рус eng 中文 عربي esp por fra tgl msa
рус eng 中文 عربي esp por fra tgl msa

О Спутник V

Список статей по безопасности векторов аденовируса человека

Название исследования
Год
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine a dose-escalation, open-label, non-randomised, first-in-human trial
2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
2020
A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes
2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
2020
Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
2020
The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism
2020
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
2020
Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
2019
State‐of‐the‐art human adenovirus vectorology for therapeutic approaches
2019
Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor
2019
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs
2019
Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
2018
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge
2018
Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
2018
Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus
2018
Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 1)
2017
Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 2)
2017
Векторные вакцины против болезни,вызванной вирусом Эбола
2017
Safety profile of a replication‐deficient human adenovirus‐vectored foot‐and‐mouth disease virus serotype A24 subunit vaccine in cattle
2017
Recent advances in genetic modification of adenovirus vectors for cancer treatment
2017
32 - Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
2016
Adenoviral vector-based strategies against infectious disease and cancer
2016
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
2016
IMMUNOBIOLOGICAL DRUG AND METHOD FOR USING SAME FOR INDUCING SPECIFIC IMMUNITY AGAINST THE EBOLA VIRUS
2016
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats
2015
High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial
2015
Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy Malaria-Naïve adults
2015
Induction of HIV-1–specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans
2015
A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative african adults
2015
A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults
2015
Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection
2014
First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)
2014
Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial
2014
A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity
2013
Viral vectors for vaccine applications
2013
Using Multivalent Adenoviral Vectors for HIV Vaccination
2013
Interleukin-Encoding Adenoviral Vectors as Genetic Adjuvant for Vaccination against Retroviral Infection
2013
Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans, Vaccine
2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin
2013
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age
2013
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine
2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity
2013
Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans
2013
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
2012
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
2012
Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines
2012
Adenovirus 5-vectored P.falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)
2011
The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert
2010
Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Response
2010
Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus
2009
Advanced Malignant Pleural orPeritoneal Effusion in Patients Treatedwith Recombinant Adenovirus p53Injection plus Cisplatin
2008
Adenoviruses: Malignant Transformation and Oncology
2008
Adenovirus 5 and 35 vectors expressingPlasmodium falciparumcircumsporozoite surface protein elicit potent antigenspecificcellular IFN-and antibody responses in mice
2008
A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults, Vaccine
2008
Role of MyD88 and TLR9 in the Innate Immune ResponseElicited by Serotype 5 Adenoviral Vectors
2007
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine
2007
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity
2006
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
2005
Adenoviral vectors: a promising tool for gene therapy
2005
Good Manufacturing Practice Production of Adenoviral Vectors for Clinical Trials
2005
Gene therapy clinical trials worldwide 1989–2004—an overview
2004
Adenoviruses as Vaccine Vectors
2004
Safety of Adenoviral Vectors: Results ofClinical Investigations in 445 Cancer PatientsTreated with Advexin® (Adenoviral p53) GeneTherapy
2004
Adenoviral vectors for gene transfer and therapy
2004
Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins
2004
Immunogenicity of Recombinant Adenovirus Serotype 35Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity
2004
Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission
2004
Production of adenovirus vector for gene therapy
2002
Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
2002
A New Vector System with Inducible E2a Cell Line for Production of Higher Titer and Safer Adenoviral Vectors
2000
Human adenovirus type 5 vectors expressing rabies glycoprotein
1996
Adenovirus vectors as recombinant viral vaccines
1995
Gene therapy using adenoviral vectors
1994
Adenoviruses as expression vectors and recombinant vaccines
1990

Ваше сообщение успешно отправлено!

Вы подписаны на наши новости
Спасибо!